Ausdal Financial Partners Inc. Acquires New Shares in Guardant Health, Inc. (NASDAQ:GH)

Ausdal Financial Partners Inc. bought a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 7,000 shares of the company’s stock, valued at approximately $214,000.

A number of other institutional investors have also added to or reduced their stakes in GH. R Squared Ltd bought a new position in shares of Guardant Health in the 4th quarter worth $26,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health in the fourth quarter valued at about $43,000. Kimelman & Baird LLC bought a new position in Guardant Health in the fourth quarter worth about $58,000. Quantbot Technologies LP purchased a new stake in shares of Guardant Health during the fourth quarter valued at about $80,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Guardant Health by 43.5% in the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after buying an additional 817 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on GH shares. Morgan Stanley boosted their price objective on shares of Guardant Health from $42.00 to $52.00 and gave the stock an “overweight” rating in a research note on Thursday, March 6th. Stifel Nicolaus increased their price objective on Guardant Health from $45.00 to $53.00 and gave the company a “buy” rating in a report on Friday, February 21st. Barclays began coverage on Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 target price on the stock. Piper Sandler raised their price target on Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Finally, Raymond James restated an “outperform” rating and set a $59.00 price objective (up previously from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $48.95.

Guardant Health Trading Down 4.5 %

Guardant Health stock opened at $43.14 on Friday. The firm has a market cap of $5.32 billion, a PE ratio of -12.12 and a beta of 1.50. Guardant Health, Inc. has a 12 month low of $15.81 and a 12 month high of $50.89. The stock’s 50 day simple moving average is $44.66 and its two-hundred day simple moving average is $34.24.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to analyst estimates of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. On average, equities research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.